{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06262477",
            "orgStudyIdInfo": {
                "id": "NL-TCZ-12280"
            },
            "organization": {
                "fullName": "Biogen",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra\u00ae in Healthy Male Participants",
            "officialTitle": "A Randomized, Double-Blind, Parallel-Group, Phase I Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 s.c. Compared to Actemra\u00ae in Healthy Male Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-pharmacokinetics-safety-and-immunogenicity-of-subcutaneously-sc-compared-to-actemra-in-healthy-male-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-08",
            "studyFirstSubmitQcDate": "2024-02-08",
            "studyFirstPostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Biogen",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BIIB800",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single dose of BIIB800 via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.",
                    "interventionNames": [
                        "Drug: BIIB800"
                    ]
                },
                {
                    "label": "Actemra",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single dose of Actemra via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.",
                    "interventionNames": [
                        "Drug: Actemra"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BIIB800",
                    "description": "Administered as specified in the treatment arm.",
                    "armGroupLabels": [
                        "BIIB800"
                    ],
                    "otherNames": [
                        "BAT1806"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Actemra",
                    "description": "Administered as specified in the treatment arm.",
                    "armGroupLabels": [
                        "Actemra"
                    ],
                    "otherNames": [
                        "Tocilizumab",
                        "RoActemra"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Serum Concentration (Cmax) of Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Apparent Total Body Clearance (CL/F) of BIIB800 and Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Apparent Terminal Half-Life (t1/2) of BIIB800 and Tocilizumab",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "From screening up to Day 57"
                },
                {
                    "measure": "Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Maximum Observed Effect (Emax) of sIL-6R",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Time to Emax (tEmax) of sIL-6R",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "AUE of High Sensitive C-Reactive Protein (hsCRP)",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Minimum Observed Effect Emin of hsCRP",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Time to Emin (tEmin) of hsCRP",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAbs)",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                },
                {
                    "measure": "Number of Participants With ADA Titers",
                    "timeFrame": "Pre-dose and at multiple timepoints up to Day 57"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Have a body mass index between 18.5 and 29.9 kilograms per meter square (kg/m\\^2), inclusive.\n* Total body weight between 60.0 and 90.0 kg, inclusive.\n* Systolic blood pressure \\<135 millimeters of mercury (mmHg) or \\>85 mmHg at Screening, after being supine for at least 5 minutes.\n* No clinically significant (as determined by the Investigator) 12-lead electrocardiogram (ECG) abnormalities, no cardiac pacemaker.\n\nKey Exclusion Criteria:\n\n* History or positive test result at Screening for human immunodeficiency virus (HIV).\n* History of hepatitis C infection or positive test result at Screening for hepatitis C virus antibody.\n* Current hepatitis B infection (defined as positive for hepatitis B surface antigen \\[HBsAg\\] and total hepatitis B core antibody \\[anti-HBc\\]).\n* Serious infection (as determined by the Investigator) within the 6 months prior to Screening.\n* History of systemic hypersensitivity reaction to the active drug substance, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.\n* History of immunodeficiency or other clinically significant immunological disorders, or autoimmune disorders.\n* History of clinically significant (in the opinion of the Investigator) atopic allergy (e.g., asthma, urticaria, eczematous dermatitis, allergic rhinitis), hypersensitivity, or allergic reactions.\n* History of angioedema.\n* A positive diagnostic tuberculosis test result within 35 days prior to Day -1, defined as a positive QuantiFERON\u00ae test result or 2 successive indeterminate QuantiFERON test results.\n* Any prior exposure to tocilizumab or to any other agent directly acting on IL-6 or on its receptors including investigational products (e.g., siltuximab, sarilumab etc.).\n* Administration of immunoglobulins for anti-tetanus and anti-rabies post-exposure prophylaxis within 3 weeks prior to administration of study drug.\n* Any live or attenuated immunization or vaccination given within 30 days prior to Day -1 or planned to be given during the study period.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": true,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US Biogen Clinical Trial Center",
                    "role": "CONTACT",
                    "phone": "866-633-4636",
                    "email": "clinicaltrials@biogen.com"
                },
                {
                    "name": "Global Biogen Clinical Trial Center",
                    "role": "CONTACT",
                    "email": "clinicaltrials@biogen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Biogen",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Fortrea Clinical Research Unit Inc.",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53704",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "608-210-5574",
                            "email": "sarah.russell@fortrea.com"
                        },
                        {
                            "name": "Sarah Russell, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}